Quantum-Si has demonstrated detection of all 20 naturally occurring amino acids in its Proteus development program, achieving its year-end 2026 goal ahead of schedule. It is working to incorporate that detection into a developmental sequencing kit for Proteus instruments.
QSI · Quantum-Si Inc · Documents
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
Quantum SI says Proteus remains on track for a second quarter 2027 launch, expects detection of the 20th amino acid before the end of the year, and has sufficient capital through the fourth quarter of 2028.
Quantum-Si reported nine-month revenue down 59.0% and net loss of $67.5 million, while an August 2026 restructuring terminated approximately 20% of its 152 employees. Proteus is estimated to launch in the second quarter of 2027.
Quantum-Si reported third-quarter revenue of $212,000, down from $552,000, as the Platinum-to-Proteus transition continued. Proteus remains on track for a Q2 2027 launch, while 2026 revenue guidance stayed at approximately $1.0 million and cash runway was reaffirmed into Q4 2028.
Quantum-Si regained compliance with Nasdaq's minimum bid price requirement as of October 13, 2026, closing the matter. The company will keep monitoring its bid price, and a future shortfall could again trigger delisting notice.
Quantum-Si demonstrated detection of 19 amino acids in its Proteus development program and is working to deploy the capability into a developmental sequencing kit; it remains confident in demonstrating detection of all 20 amino acids by year-end 2026.
Quantum-Si said interim Proteus data showed 30 times more single-chamber alignments than Platinum Pro, a 4.8-fold lower median false discovery rate, and detection of all 24 proteins in a 24-protein panel; Proteus remains on track for Q2 2027.